Related Experiment Videos
Controversies in the management of Kawasaki disease
1Division of Rheumatology, IWK Health Centre, 5850 University Ave, Halifax, Nova Scotia Canada.
Insights
Kawasaki disease (KD) treatment guidelines are established, but controversies remain regarding intravenous immunoglobulin (IVIG) dosing, aspirin (ASA) use, and managing atypical cases. Further research is needed for optimal patient care and long-term outcomes.
Area of Science:
- Pediatric Cardiology
- Rheumatology
- Immunology
Background:
- Kawasaki disease (KD) is a critical pediatric illness affecting blood vessels.
- Standard treatment protocols exist, but specific management aspects remain debated.
- Coronary artery abnormalities (CAA) are a major concern in KD patients.
Purpose of the Study:
- To review current controversies in Kawasaki disease management.
- To evaluate the evidence for different treatment modalities.
- To discuss long-term follow-up and emerging interventions.
Main Methods:
- Literature review of pertinent studies and meta-analyses.
- Analysis of evidence regarding intravenous immunoglobulin (IVIG) and aspirin (ASA) efficacy.
- Examination of treatment approaches for atypical and complex KD cases.
Main Results:
- IVIG at 2g/kg single dose is supported by strong evidence.
- Lower aspirin doses may be adequate for acute KD management.
- Corticosteroids show potential for IVIG-refractory cases; further study is needed.
Conclusions:
- While IVIG is standard, optimal aspirin dosing and management of atypical KD require more research.
- Long-term follow-up strategies for patients with and without CAA need consensus.
- Cardiac transplantation is an established option for severe, refractory KD cases.
Abstract:
While there is a generally accepted standard approach to the management of Kawasaki disease (KD) in North America, controversy still exists regarding certain aspects of treatment. Do all patients require treatment with intravenous immunoglobulin (IVIG)? What is the appropriate dose of aspirin (ASA) during the acute phase of the disease? Is there a role for corticosteroids in those who fail IVIG? How should patients with atypical, incomplete or late presentations of KD be managed? What is the appropriate long-term management and follow-up, particularly for those without coronary artery abnormalities (CAA)? Is there a role for surgical intervention, particularly transplantation? These questions, among others, are explored with reference to the pertinent literature.IVIG has been well studied and shown to be efficacious in a number of studies and in two meta-analyses, with clear evidence to support the use of 2g/kg in a single dose. The appropriate dose of ASA during the acute phase is less clear but, increasingly, data suggest that lower doses of ASA are adequate and perhaps more appropriate. Corticosteroids appear to have a role in those who have failed IVIG but this requires further study before being embraced as accepted treatment. The management of less typical presentations of KD remains controversial, with inadequate data to direct us, although there is a general trend towards treating such patients with IVIG. Careful follow-up of all patients is recommended and, while there are guidelines for this, there is no clear consensus on the most appropriate monitoring investigations for those with and without CAA. There is an expanding role for transplantation, with clearly defined indications for this intervention.